Media contacts:
Ron Sauder (for Emory) 404/727-3366,
Melissa Katz (for Janssen) 609/730-2612
May 20 , 2002


Janssen Pharmaceutica Endows Psychiatry Chair at Emory University

Janssen Pharmaceutica, L.P. is committing $1.5 million to endow the Paul Janssen Chair in Neuropsychopharmacology at the Emory University School of Medicine. The gift commitment from Janssen honors the company's 75-year-old founder Paul Janssen, PhD, MD. Emory has one of the nation's largest and most rapidly growing research groups in the study of drugs and their effects on the human mind, brain, and behavior.

The new chair will be located in the Department of Psychiatry and Behavioral Sciences, where 13 faculty researchers are members of the American College of Neuropsychopharmacology -- the leading national consortium of scientists devoted to studying both natural and synthetic compounds used in the treatment of anxiety, depression, schizophrenia and other mental and behavioral disorders.

"The Paul Janssen Chair is a wonderful tribute to a man who has been one of the most highly productive and widely esteemed pharmacological researchers in the world for more than 45 years," said Charles B. Nemeroff, M.D., Ph.D., the Reunette W. Harris professor and chair of psychiatry and behavioral sciences. "It is gratifying to know that with the establishment of this chair, the Janssen name will be linked forever to research in the Department of Psychiatry and Behavioral Sciences at Emory. We depend on extraordinary support such as this to maintain the pace of discovery in one of the most exciting areas in all of medicine."

Researchers in the department are working at the molecular, cellular, and behavioral levels to understand how existing psychotropic drugs affect the brain and to identify promising new targets in the brain for future drugs. Researchers use MRI, PET, SPECT, and MRS imaging equipment for both human and animal studies of brain activity and response. Departmental researchers in the Emory University Hospital also work in clinical studies of patients suffering from mood and anxiety disorders, schizophrenia, and Alzheimer's disease.

A leading area of research is the relationship of stress to mood and anxiety disorders. The department is also recognized for its studies of the neurobiological basis of schizophrenia and for the psychiatric effects of drugs on nursing mothers and infants.

"The Paul Janssen Chair is a very welcome commitment that gives us the option of either recruiting or retaining a world-class faculty researcher in psychiatry and behavioral sciences," said Thomas J. Lawley, M.D., dean of the School of Medicine. "We are particularly dedicated to supporting cutting-edge researchers who are actively involved in training graduate and medical students -- who will, in their turn, populate the next generation of investigators in this field. This gift thus allows us to support and extend one of the most vital communities of scientists devoted to neuropsychopharmacology to be found anywhere."


Janssen Pharmaceutica Products, L.P. produces and markets prescription pharmaceuticals for use in psychiatry, neurology, gastroenterology, pain management and dermatology.

After the breakthrough of Haldol, Dr. Paul Janssen followed with the discovery of the now first-line atypical, Risperdal" (risperidone), the most widely prescribed atypical antipsychotic in the world. Five Janssen drugs are on the World Health Organization's critical list of essential drugs. During his career Dr. Janssen is responsible for discovering over 25 psychotherapeutics.

Janssen's U.S. operations are based in Titusville, New Jersey, and its international headquarters are in Beerse, Belgium. Dr. Paul Janssen, a renowned physician and chemist, founded the company in Belgium. In the early 1960s it became a part of the Johnson & Johnson family of companies. Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products and provides related health care services for the consumer, pharmaceutical and professional markets.


Paul Adriaan Jan Janssen

Dr. Paul

A man of genius

Belgium, Turnhout, 12 September 1926

Dr. Paul is one of the world's foremost medical scientists, whose research has resulted in treatments and improvements for countless illnesses, in a wide variety of diseases, ranging from mycotic infections to mental illnesses, from gastrointestinal to parasitic diseases, from anaesthetics to products for veterinary medicine, plant and wood protection. In total, more than 75 drugs were developed under his inspirational guidance.

Dr. Paul has served Janssen Pharmaceutica as president and director of research for 33 years. The company has now 34 international affiliates with some 20,000 employees world-wide.

Dr. Paul is known throughout the world as an outstanding physician, pharmaceutical chemist, inventor and mentor to many scientists. As a result of over 45 years of research and development work through his pharmaceutical company, Dr. Paul holds over 100 drug patents.

His formidable contributions to the world of medical science have been justly recognized with 21 honorary doctorate degrees and five honorary professorships from 16 different countries. His worldwide awards, honours and appointments number close to 100, among them the International Galenus Prize for Risperdal, the Pioneer in Science Award from the United States' National Alliance for the Mentally Ill, the Psychiatric Times' Lifetime Achievement Award, the Taylor Manor Hospital Psychiatric Award, the Gairdner Foundation Award, the Discoverers' Award, Pharmaceutical Manufacturers Association, the Award in Medicinal Chemistry, American Chemical Society, Carothers Award, American Chemical Society, Distinguished Service Award, American College of Clinical Pharmacology, Honorary Professor in Clinical Dermatology, Stanford University.

He is currently a member of 20 international associations, colleges and societies, and holds four directorships. Throughout his career, Dr. Paul has contributed a vast amount of knowledge to pharmaceutical science. He has authored or co-authored more than 800 scientific publications and presented more than 500 scientific lectures in any of five languages.

Dr. Paul has always been the personification of a unique combination : on the one hand the brilliant scientist, and on the other the very successful manager. Nevertheless, he has never wished to take all the credit for himself. His elevation to the Belgian peerage with the titel of Baron, is not just a personal accolade but above all a token of recognition of the achievements of all those people who have assisted over the years and dedicated their best efforts in spreading the excellent reputation that Janssen Pharmaceutica has earned within just a few decades all over the world.

'I wish to continue to devote my energies to the improvement of health care because there is still so much more to be done.'

-- Dr. Paul Janssen

Return to May Index

For more general information on The Robert W. Woodruff Health Sciences Center
call Health Sciences Communication's Office at 404-727-5686,
or send e-mail to

Copyright © Emory University, 2001. All Rights Reserved.